EnBiotix
Benjamin Perrone has worked in various business development and finance roles in companies such as Spexis AG, Proterris, Inc., EnBiotix, Inc., and Boston University Office of Technology Development. With a background in Physics and a Ph.D. in Biomedical Engineering, Benjamin has a strong foundation for their career in developing life-changing therapies for rare disease and oncology patients.
EnBiotix
EnBiotix is a late clinical-stage rare disease company currently focused on therapies for cystic fibrosis, non-CF bronchiectasis, and non-tuberculosis mycobacterial infections, a $15 billion global market.